Analyzing Zevra Therapeutics (ZVRA) and The Competition

Zevra Therapeutics (NASDAQ:ZVRA) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Zevra Therapeutics to related companies based on the strength of its dividends, institutional ownership, analyst recommendations, earnings, profitability, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Zevra Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0	1	9	1	3.00
Zevra Therapeutics Competitors	7752	13841	25682	1031	2.41

Zevra Therapeutics presently has a consensus target price of $27.14, suggesting a potential upside of 165.59%. As a group, “Pharmaceuticals” companies have a potential upside of 23.74%. Given Zevra Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than its peers.

Volatility and Risk

Zevra Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Zevra Therapeutics’ peers have a beta of -4.34, suggesting that their average share price is 534% less volatile than the S&P 500.

Insider & Institutional Ownership

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Zevra Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zevra Therapeutics	$106.47 million	$83.23 million	11.11
Zevra Therapeutics Competitors	$3.54 billion	$3.18 billion	545.59

Zevra Therapeutics’ peers have higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Zevra Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Zevra Therapeutics Competitors	-2,380.63%	-221.06%	-16.01%

Summary

Zevra Therapeutics beats its peers on 9 of the 13 factors compared.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.